Maximizing Corporate Value Through Investment in Drug Development
First written in FY2016. 8 of 10 entries say "Restated". Latest entry: FY2025.
1 other company's latest entry also says "Restated".
- FY2025RestatedAnnual report
「Accordingly, in developing these pharmaceuticals and diagnostic products, the Group will carefully consider whether it can conduct the entire process through commercialization in-house, taking into account its human resources and operational efficiency. In product development, it will pursue maximum corporate value through proactive, selective and focused investment, adding value to its antibodies and strengthening its pipeline.」
The company continues its policy of enhancing corporate value through selective and focused investment based on its human resources and operational efficiency, investment in diagnostic and pharmaceutical development, and adding value to its antibodies. - FY2023RestatedAnnual report
「Accordingly, in developing these pharmaceuticals and diagnostic products, the Group will carefully consider whether it can conduct the entire process through commercialization in-house, taking into account its human resources and operational efficiency. In product development, it will pursue maximum corporate value by making proactive, selective and focused investments, adding value to its antibodies and strengthening its pipeline.」
The company continues its policy of maximizing corporate value through selective and focused investment based on its human resources and operational efficiency, proactive product development investment and pipeline expansion. - FY2023-Q3ReframedAnnual report
「To achieve a stable financial position and enhance corporate value, approximately ¥350 million will be required for the development of in vitro diagnostic products and related raw materials, with spending planned from April 2023 to March 2025. The company therefore decided to make this change.」
The focus of investment aimed at enhancing corporate value changed from funding nonclinical and clinical trials for anti-HIV antibodies to funding the development of in vitro diagnostic products and related raw materials. - FY2021RestatedAnnual report
「Accordingly, in developing these pharmaceuticals and diagnostic products, the Group will carefully consider whether it can conduct the entire process through commercialization in-house, taking into account its human resources and operational efficiency. In product development, it will pursue maximum corporate value by making proactive, selective and focused investments, adding value to its antibodies and strengthening its pipeline.」
The company continues its policy of maximizing corporate value through selective and focused research and development investment, adding value to its antibodies and strengthening its pipeline. - FY2019RestatedAnnual report
「As described above, the Group seeks to maximize corporate value through proactive investment in pharmaceutical development, adding value to its antibodies and strengthening its pipeline.」
The company has reiterated its policy of maximizing corporate value through investment in pharmaceutical development, adding value to its antibodies and strengthening its pipeline. - FY2019-Q3RestatedAnnual report
「In this business, the company will continue to make proactive investments in research and development and aims to enhance corporate value over the medium to long term.」
The company has reaffirmed its policy of enhancing corporate value over the medium to long term through continued investment in research and development in its genetically modified silkworm business. - FY2019-Q1RestatedAnnual report
「In this business, the company will continue to make proactive investments in research and development and aims to enhance corporate value over the medium to long term.」
The company has reaffirmed its policy of enhancing corporate value over the medium to long term through continued investment in research and development in its genetically modified silkworm business. - FY2018-Q1RestatedAnnual report
「In this business, the company will continue to make proactive investments in research and development and aims to enhance corporate value over the medium to long term.」
The company has reaffirmed its policy of enhancing corporate value over the medium to long term through continued investment in research and development in its genetically modified silkworm business. - FY2017RestatedAnnual report
「As described above, the Group seeks to maximize corporate value through proactive investment in pharmaceutical development, adding value to its antibodies and strengthening its pipeline.」
The company has reaffirmed its aim of maximizing corporate value through investment in pharmaceutical development, adding value to its antibodies and strengthening its pipeline. - FY2016First statedAnnual report
「As described above, the Group seeks to maximize corporate value through proactive investment in pharmaceutical development, adding value to its antibodies and strengthening its pipeline.」
The company identifies proactive investment in pharmaceutical development, adding value to its antibodies and strengthening its pipeline as means of increasing corporate value.